Shoreline Biosciences  CEO Kleanthis Xanthopoulos, Ph.D. joins the Business of Biotech to share the company's strategy for the development, manufacture, and commercialization of off-the-shelf NK (natural killer) cell therapy. On this episode,  Dr. Xanthopoulos shares why the cell and gene immunotherapeutic market has underperformed to date, why he believes autologous is not the long-term path forward, and  the safety and accessibility advantages he sees in his allogeneic-based, pluripotent stem cell approach. Visit www.bioprocessonline.com to learn how another emerging biopharma is leveraging allogeneic NK cells in oncology.